Mupirax (Mupirocin 2%) Ointment
1. Category
Topical antibacterial agent, protein synthesis inhibitor.
2. Active Ingredient
Mupirocin 2% (20 mg per gram of ointment).
3. Mechanism of Action
Mupirocin inhibits bacterial protein and RNA synthesis by binding to isoleucyl-tRNA synthetase, blocking isoleucine incorporation into proteins. It shows no cross-resistance with other antibiotic classes.
4. Indications
- Primary & secondary superficial skin infections.
- Impetigo, folliculitis, and furunculosis caused by Staphylococcus aureus (including MRSA), Streptococcus pyogenes.
- Burn wound infections due to MRSA.
- Infected wounds and lacerations.
5. Available Forms
- Mupirax 2% ointment, 10 g tube (GLOBAL NAPI PHARMACEUTICALS).
- Mupirax 2% ointment, 30 g tube (GLOBAL NAPI PHARMACEUTICALS).
6. Dosage & Administration
Apply a small amount to the affected area up to three times daily for up to 10 days. The area may be covered with a dressing if required. For topical use only. Not for ophthalmic or intranasal administration.
7. Pharmacokinetics
Minimal systemic absorption. Penetration increases in damaged skin or under occlusion. Polyethylene glycol (PEG) base can be absorbed through open wounds and excreted by the kidneys.
8. Contraindications
- Hypersensitivity to mupirocin or any of the excipients (including polyethylene glycol).
- Not suitable for ophthalmic or intranasal use.
9. Precautions & Warnings
- Avoid eye contact when applying to the face.
- Use with caution in patients with moderate to severe renal impairment due to potential PEG absorption.
- Discontinue if severe local irritation or hypersensitivity reactions occur.
10. Side Effects
- Local: burning, stinging, itching at application site.
- Rare: erythema, rash, contact dermatitis, swelling.
- Very rare: systemic hypersensitivity reactions.
11. Drug Interactions
No significant systemic drug interactions due to negligible absorption. Avoid concurrent use with other topical agents on the same site unless advised by a physician.
12. Use in Pregnancy & Lactation
Animal studies show no teratogenic effects, but human data are limited. Use only if clearly needed during pregnancy. Caution during breastfeeding; avoid application to the breast area.
13. Pediatric Use
Safe and effective in children for indicated skin infections. Apply under medical supervision.
14. Geriatric Use
No specific dose adjustment required, but consider renal function due to PEG base absorption.
15. Overdose
Topical overdose is unlikely. Ingestion may cause nausea, vomiting, and gastrointestinal upset. Treat symptomatically.
16. Storage
Store at room temperature (below 25°C). Keep out of reach of children. Do not freeze.
17. Packaging
Aluminum tubes of 10 g and 30 g ointment, packed with patient leaflet insert.
18. Manufacturer
GLOBAL NAPI PHARMACEUTICALS, Egypt.
19. Frequently Asked Questions (FAQ)
Q1: Can I use Mupirax for nasal infections?
No. This formulation is not suitable for intranasal use.
Q2: How long should I use Mupirax?
Usually up to 10 days, or as directed by your doctor.
Q3: Is Mupirax effective against MRSA?
Yes, Mupirax is active against methicillin-resistant Staphylococcus aureus (MRSA).
Q4: Can I cover the treated area with a dressing?
Yes, the treated area may be covered with a sterile dressing if needed.
Q5: What should I do if irritation occurs?
Stop using Mupirax and consult your doctor immediately.